NYSE · RVTYHealthcareLab Analytical Instruments

Revvity financials

$152.77+1.16%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 28
FY24
Dec 29
FY23
Dec 31
Revenue$2.86B$2.76B$2.75B
Gross profit$1.56B$1.54B$1.54B
Gross margin54.8%55.8%56.0%
Operating income$356.6M$346.7M$300.6M
Net income$241.2M$270.4M$693.1M
Net margin8.4%9.8%25.2%
Diluted EPS$2.07$2.20$5.55
EBITDA$762.0M$774.6M$732.3M
Operating cash flow$582.9M$628.3M$91.3M
Free cash flow$509.4M$541.7M$9.9M
Diluted shares116.6M122.8M124.8M

Balance sheet

Period endDec 28Dec 29Dec 31
Cash & equivalents$919.9M$1.16B$913.2M
Short-term investments$0.00$0.00$689.9M
Total debt$3.22B$3.15B$3.90B
Total assets$12.17B$12.39B$13.56B
Total liabilities$4.92B$4.73B$5.69B
Shareholders' equity$7.25B$7.67B$7.87B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology